Logo image of BSGM

BIOSIG TECHNOLOGIES INC (BSGM) Stock Fundamental Analysis

NASDAQ:BSGM - Nasdaq - US09073N3008 - Common Stock - Currency: USD

4.63  -0.12 (-2.53%)

After market: 4.72 +0.09 (+1.94%)

Fundamental Rating

2

Overall BSGM gets a fundamental rating of 2 out of 10. We evaluated BSGM against 187 industry peers in the Health Care Equipment & Supplies industry. While BSGM has a great health rating, there are worries on its profitability. BSGM does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

BSGM had negative earnings in the past year.
BSGM had a negative operating cash flow in the past year.
In the past 5 years BSGM always reported negative net income.
BSGM had a negative operating cash flow in each of the past 5 years.
BSGM Yearly Net Income VS EBIT VS OCF VS FCFBSGM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

BSGM has a worse Return On Assets (-221.49%) than 94.12% of its industry peers.
With a Return On Equity value of -361.25%, BSGM is not doing good in the industry: 85.03% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -221.49%
ROE -361.25%
ROIC N/A
ROA(3y)-1196.25%
ROA(5y)-793.27%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BSGM Yearly ROA, ROE, ROICBSGM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BSGM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BSGM Yearly Profit, Operating, Gross MarginsBSGM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50K -100K -150K

More info and screens

7

2. Health

2.1 Basic Checks

BSGM does not have a ROIC to compare to the WACC, probably because it is not profitable.
BSGM has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, BSGM has more shares outstanding
BSGM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BSGM Yearly Shares OutstandingBSGM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
BSGM Yearly Total Debt VS Total AssetsBSGM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

An Altman-Z score of 131.17 indicates that BSGM is not in any danger for bankruptcy at the moment.
BSGM's Altman-Z score of 131.17 is amongst the best of the industry. BSGM outperforms 100.00% of its industry peers.
BSGM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 131.17
ROIC/WACCN/A
WACC9.08%
BSGM Yearly LT Debt VS Equity VS FCFBSGM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M

2.3 Liquidity

BSGM has a Current Ratio of 2.38. This indicates that BSGM is financially healthy and has no problem in meeting its short term obligations.
BSGM has a Current ratio of 2.38. This is comparable to the rest of the industry: BSGM outperforms 44.38% of its industry peers.
BSGM has a Quick Ratio of 2.38. This indicates that BSGM is financially healthy and has no problem in meeting its short term obligations.
BSGM's Quick ratio of 2.38 is in line compared to the rest of the industry. BSGM outperforms 54.55% of its industry peers.
Industry RankSector Rank
Current Ratio 2.38
Quick Ratio 2.38
BSGM Yearly Current Assets VS Current LiabilitesBSGM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

More info and screens

1

3. Growth

3.1 Past

BSGM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 82.54%, which is quite impressive.
The Revenue for BSGM has decreased by -25.93% in the past year. This is quite bad
The Revenue for BSGM have been decreasing by -55.07% on average. This is quite bad
EPS 1Y (TTM)82.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%61.11%
Revenue 1Y (TTM)-25.93%
Revenue growth 3Y-55.07%
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, BSGM will show a very strong growth in Earnings Per Share. The EPS will grow by 33.64% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y68.52%
EPS Next 2Y33.64%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BSGM Yearly Revenue VS EstimatesBSGM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M
BSGM Yearly EPS VS EstimatesBSGM Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2020 2021 2022 2023 2024 2025 2026 -5 -10 -15 -20

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BSGM. In the last year negative earnings were reported.
Also next year BSGM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BSGM Price Earnings VS Forward Price EarningsBSGM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BSGM Per share dataBSGM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4

4.3 Compensation for Growth

BSGM's earnings are expected to grow with 33.64% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.64%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BSGM!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOSIG TECHNOLOGIES INC

NASDAQ:BSGM (7/18/2025, 8:00:01 PM)

After market: 4.72 +0.09 (+1.94%)

4.63

-0.12 (-2.53%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-19 2025-05-19/dmh
Earnings (Next)08-12 2025-08-12
Inst Owners8.81%
Inst Owner Change-0.5%
Ins Owners3.82%
Ins Owner Change10.21%
Market Cap631.35M
Analysts82.86
Price Target10.2 (120.3%)
Short Float %1.04%
Short Ratio1.1
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-45.91%
Min EPS beat(2)-174.51%
Max EPS beat(2)82.7%
EPS beat(4)2
Avg EPS beat(4)-61.19%
Min EPS beat(4)-194.12%
Max EPS beat(4)82.7%
EPS beat(8)3
Avg EPS beat(8)-43.54%
EPS beat(12)4
Avg EPS beat(12)-29.73%
EPS beat(16)6
Avg EPS beat(16)-22.72%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)300%
PT rev (3m)263.64%
EPS NQ rev (1m)0%
EPS NQ rev (3m)77.78%
EPS NY rev (1m)0%
EPS NY rev (3m)65.75%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 31567.34
P/FCF N/A
P/OCF N/A
P/B 232.97
P/tB 258.75
EV/EBITDA N/A
EPS(TTM)-0.59
EYN/A
EPS(NY)-0.17
Fwd EYN/A
FCF(TTM)-0.03
FCFYN/A
OCF(TTM)-0.03
OCFYN/A
SpS0
BVpS0.02
TBVpS0.02
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -221.49%
ROE -361.25%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-1196.25%
ROA(5y)-793.27%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.38
Quick Ratio 2.38
Altman-Z 131.17
F-Score5
WACC9.08%
ROIC/WACCN/A
Cap/Depr(3y)36.29%
Cap/Depr(5y)95.03%
Cap/Sales(3y)364.03%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)82.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%61.11%
EPS Next Y68.52%
EPS Next 2Y33.64%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-25.93%
Revenue growth 3Y-55.07%
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y48.95%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y78.83%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y78.68%
OCF growth 3YN/A
OCF growth 5YN/A